PRESS RELEASE: Omicron variant fastest healthcare product launch since Black Death
Pestilence equals profit
SIOUX FALLS, VALLETTA, Malta & BEIJING, China — (BUSINESS WIRE) — Deep State Holdings LLC (NYSE:DEEP; HKEX:08666), a multinational conglomerate engaged in the development, manufacturing, and distribution of high-innovation products in fast-growing, globalized markets, is proud to announce its newly approved Omicron variant (“Omi”) has become the most successful healthcare product launch in documented history.
“The rapid adoption of Omicron is a testament to our continued commitment to consumers in the infectious and communicable diseases category,” said Thomas Jeffrey “Tom” Hanks, Deep State’s Executive Chairman and Chief Executive Officer.
“From the moment our R&D team dreamt up Omi, a heavily mutated variation of our highly successful Alpha and Delta brands, our entire company has worked tirelessly to ensure a successful launch. Given our broad distribution, dominant global market share, and remarkable early sales trajectory, I’d say we’ve risen to the challenge,” Mr. Hanks added.
Joseph James “Joe” Rogan, Global Head of Sales & Marketing, said: “Omi has achieved unprecedented scale following our soft launch in South Africa last November. Since then, we’re extremely pleased to see that, given its widespread availability and user-friendly interface, consumers around the globe have rapidly switched to Omi. We expect Omi to remain the leading infectious disease brand until our highly anticipated Pi update is released during the third quarter of 2022.”
RECENT OMICRON LAUNCH HIGHLIGHTS
One day global record 3.7 million adopters on January 12, 2022
One day U.S. record 1.4 million adopters on January 10, 2022
Over 95% U.S. market share
Deep penetration into recalcitrant Australian market
Strong “Make the Switch” ad campaign by long-time brand ambassador Novak Djokovic
“Mild virulence” product segmentation receives 93% favorability rating among U.S. consumers
77% of Democrats and 96% of Republicans agree Omicron is the SARS-CoV-2 variant of choice
ADJACENT SEGMENT HIGHLIGHTS
In addition to the record-setting launch of Omicron, Deep State is pleased to announce the following business updates, which will be discussed in more detail at an upcoming investor conference.
Vaccines division: Deep State’s Pfizer Inc. (NYSE:PFE) and Moderna, Inc. (NASDAQ:MRNA) subsidiaries continue to dominate global COVID-19 vaccine market share, though demand has slowed in the U.S. and other Western European markets. While the global vaccine opportunity remains exceptionally large, lower average selling prices (“ASPs”) and distribution challenges for ROW subscribers will likely constrain net global sales growth. Demand for Pfizer and Moderna’s “booster” shots continues to surge, however, and is expected to offset modest vaccine sales declines in established markets. Deep State thus re-affirms its existing financial guidance for its vaccines division, expecting over $50 billion in net sales this year.
Facemasks division: “In tandem with the rise of Omicron, our Asian subsidiaries in South Korea, Vietnam, and China have reported record demand for N95, KN95 and KF94 facemasks. Recent inflationary pressures are also driving all-time high price points,” said Mr. Rogan.
Testing kits: Testing demand continues to outstrip supply in all developed markets. In line with recent trends, Deep State expects net testing sales to surpass $10 billion for full-year 2022, far exceeding prior annual guidance of “over $7 billion.”
Ventilators: “With our R&D group shifting virulence back to levels on par with the Alpha variant, and our unprecedented COVID-19 vaccine launches last year, we’re expecting a modest decrease in sales in our ventilators unit,” said Mehmet Cengiz Öz, “Dr. Oz”, Chief Medical Officer and Global Head of Research & Development.
Teacher strikes: “The desecration of global societies continues unabated, which leads to mass disenfranchisement, political strife, protests, violent uprisings, and despair — which creates a virtuous cash generation cycle and leads to increased penetration of our coronavirus portfolio,” said CEO Hanks. “Last week’s illegal strike by the Chicago Teachers Union was a beautiful example of how poor decision-making prolongs the pandemic and increases sales and earnings across our extremely complementary product portfolio.”
FIRST-QUARTER OMICRON FINANCIAL GUIDANCE
For the first-quarter of 2022, management expects the following Omicron metrics to be achieved:
110–125 million new global users, with user churn (“deaths”) of 630,000 to 810,000
54–72 million new U.S. users, with user churn (“deaths”) of 108,000 to 162,000
Adoption in all global countries
>99% U.S. market share
INVESTOR CONFERENCE CALL
Management looks forward to discussing Deep State’s fourth-quarter and full-year 2021 financial results and to providing full-year 2022 financial guidance during an investor call on February 14, 2022. Interested parties can watch live online at www.deepstatellc.com, or dial-in as follows:
Conference call line: +1 800-NEO-CUCK
Passcode: IVERMECTIN
ABOUT DEEP STATE HOLDINGS LLC
Deep State Holdings LLC is a multinational holding company focused on fast-growing and highly disruptive products, people, and markets. We invest in the technologies that make human existence meaningless and unbearable.
CONTACT US
Media relations:
+1 800-ANTI-VAX
deepstatemedia@deepstatellc.com
Investor relations:
+1 800-FU-PAYME
ir@deepstatellc.com